Gufic Biosciences Ltd.
has incorporated a wholly-owned subsidiary called Gufic UK, United Kingdom. The new entity will support the companyâ€™s pharmaceutical business expansion in the European markets.
The cost of acquisition is 1000 pounds, consisting of 1000 equity shares of 1 pound each.
Gufic Biosciences is an emerging pharma company known for its innovative and high-quality pharmaceutical and Herbal Products along with a wide range of APIs.
Gufic is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. The product portfolio consists of Antibiotic, Antifungal, Cardiac, Infertility, Antiviral, and proton-pump inhibitor segments.
Gufic BioSciences is currently trading at Rs236.75 down by Rs0.25 or 0.11% from its previous closing of Rs237 on the BSE. Its scrip has touched a high and low of Rs247.35 and Rs236 respectively.